PVA Share Price

Open 2.32 Change Price %
High 2.32 1 Day 0.00 0.00
Low 2.32 1 Week -0.17 -6.83
Close 2.32 1 Month -0.21 -8.30
Volume 2500 1 Year -2.98 -56.23
52 Week High 6.65
52 Week Low 2.30
PVA Important Levels
Resistance 2 2.32
Resistance 1 2.32
Pivot 2.32
Support 1 2.32
Support 2 2.32
ASX Australia Most Active Stocks
AGO 0.02 0.00%
AGO 0.02 0.00%
AGO 0.02 0.00%
AKK 0.01 0.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
TEG 0.05 0.00%
TEG 0.05 0.00%
TEG 0.05 0.00%
More..
ASX Australia Top Gainers Stocks
KSO 0.40 3900.00%
NMI 0.02 100.00%
NMI 0.02 100.00%
NMI 0.02 100.00%
RXL 0.02 100.00%
RXL 0.02 100.00%
RXL 0.02 100.00%
GBZ 0.02 100.00%
ARA 0.57 54.05%
ARA 0.57 54.05%
More..
ASX Australia Top Losers Stocks
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
TCQ 0.27 -73.53%
RMG 0.01 -50.00%
RMG 0.01 -50.00%
XST 0.01 -50.00%
XST 0.01 -50.00%
EXG 0.02 -33.33%
More..

pSivida Corp (ASX: PVA)

PVA Technical Analysis 5
As on 7th Dec 2016 PVA Share Price closed @ 2.32 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 4.74 & Strong Sell for SHORT-TERM with Stoploss of 3.94 we also expect STOCK to react on Following IMPORTANT LEVELS.
PVA Target for December
1st Target up-side 2.66
2nd Target up-side 2.78
3rd Target up-side 2.9
1st Target down-side 2.32
2nd Target down-side 2.2
3rd Target down-side 2.08
PVA Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.psivida.com
PVA Address
PVA
400 Pleasant Street
Watertown, MA 02472
United States
Phone: 617-926-5000
Fax: 617-926-5050
PVA Latest News
Filing Buzzer: Mangrove Partners Master Fund, Ltd Just Disclosed New Penn ...   Frisco Fastball   - 15th Nov 16
Penn Virginia Corp Bearish Signal George Soros's Soros Fund Management Llc ...   OctaFinance.com   - 17th Jan 16
PEG Ratio (5 yr expected):   Yahoo!7 News   - 29th Mar 14
Interactive Technical Analysis Chart pSivida Corp ( PVA ASX Australia )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on pSivida Corp
PVA Business Profile
pSivida Corp. develops products to deliver drugs and biologics primarily in the United States and the United Kingdom. The company, through its Durasert and BioSilicon technology platforms, focuses on the treatment of chronic diseases of the back of the eye. It offers ILUVIEN, an injectable sustained-release micro-insert delivering fluocinolone acetonide for the treatment of vision impairment associated with chronic diabetic macular edema; and Retisert for the treatment of posterior uveitis. The company’s ILUVIEN is also studied in two Phase II clinical trials for the treatment of the dry form of age-related macular degeneration and retinal vein occlusion. It also develops Medidur, which is in Phase III clinical trials for the treatment of posterior uveitis; TBD that is in Phase I/II clinical trial for the treatment of glaucoma; and glaucoma latanoprost product candidate, which is an injectable bioerodible drug delivery micro-insert for the treatment of glaucoma and ocular hypertension. The company has strategic collaborations with Alimera Sciences, Inc.; Pfizer, Inc.; Bausch & Lomb Incorporated; Intrinsiq Materials Cayman Limited; and Enigma Therapeutics Limited. pSivida Corp. was founded in 1987 and is headquartered in Watertown, Massachusetts.